Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer

Basit Öğe Kaydı
dc.authorid0000-0002-0077-6971
dc.authorid0000-0002-0443-6966
dc.authorid0000-0002-0600-5801
dc.authorid0000-0002-5823-1704
dc.authorid0000-0001-7934-7039
dc.authorid0000-0001-8802-6376
dc.authorid0000-0003-2715-4002
dc.contributor.authorGöktaş Aydın, Sabin
dc.contributor.authorBilici, Ahmet
dc.contributor.authorÇalış, Elif
dc.contributor.authorKutlu, Yasin
dc.contributor.authorHamdard, Jamshid
dc.contributor.authorMuğlu, Harun
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorKarcı, Ebru
dc.contributor.authorAçıkgöz, Özgür
dc.date.accessioned2023-09-29T08:36:21Z
dc.date.available2023-09-29T08:36:21Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Tıbbi Patoloji Ana Bilim Dalı
dc.description.abstractBackground: Non-small cell lung cancer (NSCLC) often exhibits elevated Secreted Protein Acidic and Cysteine-Rich (SPARC) expression. In this study, we investigated the impact of SPARC expression on clinicopathologic features, pembrolizumab response, and prognosis in metastatic NSCLC patients. Methods: Thirty-six patients diagnosed with metastatic NSCLC without actionable driver mutation and who received pembrolizumab with or without chemotherapy were included in this study. PD-L1 and SPARC expression were evaluated, with PD-L1 expression categorized based on tumor proportion score and SPARC staining intensity graded as 1+, 2+, and 3 +. Patients’ characteristics were compared across groups, and possible predictive markers were determined by binary logistic regression analysis. Results: No significant associations were found between SPARC expression and smoking status, histopathological tumor type, T and N status, and liver and bone metastasis. Higher SPARC expression was significantly linked to lower brain metastasis rates but higher CNS progression rates (p = 0.022 and p = 0.011, respectively. The objective response rate (ORR) showed a trend of being higher in the SPARC 1 + group (85.7% vs. 43.8% and 50.0% in 2 + and 3 + groups, respectively, p = 0.052. Univariate analysis did not find SPARC expression to be a significant prognostic factor for progression-free survival (PFS) (p = 0.7) and overall survival (OS) (p = 0.07).SPARC 1 + expression negatively affected the pembrolizumab response(p = 0.04,OR:0.11, 95%CI 0.01–0.92). Conclusions: Our study sheds light on a novel aspect of SPARC expression as a potential predictor of pembrolizumab response and a marker for CNS progression in metastatic NSCLC patients treated in the first-line setting.
dc.identifier.citationGöktaş Aydın, S., Bilici, A., Çalış, E., Kutlu, Y., Hamdard, J., Muğlu, H. ... Açıkgöz, Ö. (2023). Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer. International Immunopharmacology, 124. https://doi.org/10.1016/j.intimp.2023.110947
dc.identifier.doi10.1016/j.intimp.2023.110947
dc.identifier.issn1567-5769
dc.identifier.issn1878-1705
dc.identifier.pmid37742369
dc.identifier.scopus2-s2.0-85171857922
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.intimp.2023.110947
dc.identifier.urihttps://hdl.handle.net/20.500.12511/11503
dc.identifier.volume124
dc.identifier.wos001082097100001en_US
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorGöktaş Aydın, Sabin
dc.institutionauthorBilici, Ahmet
dc.institutionauthorÇalış, Elif
dc.institutionauthorKutlu, Yasin
dc.institutionauthorHamdard, Jamshid
dc.institutionauthorMuğlu, Harun
dc.institutionauthorÖlmez, Ömer Fatih
dc.institutionauthorKarcı, Ebru
dc.institutionauthorAçıkgöz, Özgür
dc.language.isoen
dc.publisherElsevier B.V.
dc.relation.ispartofInternational Immunopharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectNon-Small Cell Lung Cancer
dc.subjectPembrolizumab
dc.subjectResponse
dc.subjectSPARC Expression
dc.titleImpact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Aydin-Sabin-2023.pdf
Boyut:
7.65 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu